市场调查报告书
商品编码
1126377
慢性病管理全球市场规模,份额,行业趋势分析报告:按类型(解决方案和服务),用户(医疗保健提供者/支付者,其他),疾病类型,区域展望,预测2022-2028Global Chronic Disease Management Market Size, Share & Industry Trends Analysis Report By Type (Solutions and Services), By End User (Healthcare Providers, Healthcare Payers and Others), By Disease Type, By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,全球慢性病管理市场规模预计将达到 99 亿美元,在预测期内以 11.7% 的复合年增长率增长。
不断增长的老年人口和癌症等多种慢性病的患病率上升是推动慢性病管理市场增长的主要因素。例如,根据 NCBI,全球 43% 的疾病和 60% 的死亡是由慢性病引起的。此外,据世卫组织称,非传染性疾病 (NCD) 影响所有年龄、地理区域和国家的人。
此外,由于引入了 IT 解决方案,慢性病管理的接受度不断提高,从而推动了慢性病管理市场的增长。医疗保健专业人员、组织和付款人正在做出各种努力来帮助人们有效地管理他们的疾病。与传统的患者教育不同,它侧重于解决问题和社会应对,并努力提高护理管理中的自我效能。
COVID-19 影响分析
慢性病管理市场继续受益于 COVID-19 的整体影响。 COVID-19 发病率的上升增加了许多国家对准确诊断和治疗工具的需求。医疗保健组织在这方面显示出巨大的优势,因为它们可以轻鬆地将患者管理、EHR 和护理管理等解决方案与医疗支付方解决方案(如计费和支付管理)连接起来。此外,该疾病的全球传播导致关闭和其他限制,增加了对电子数据传输和计费管理的需求。预计慢性病管理将在未来几年变得更加普遍。
市场增长因素
各种慢性病患者增多
在预测期内,糖尿病、癌症和高血压等慢性病的发病率预计将增加,从而推动市场增长率。慢性病是老年人最关心的问题,因为他们更容易患肥胖症和糖尿病。许多接受慢性病治疗的患者面临着社会经济障碍,难以获得和支付每天的医疗保健费用。如果他们没有必要的资金,这些患者可能会推迟或放弃必要的治疗。
不断增长的老年人口
由于平均预期寿命的延长,60岁及以上的人口数量稳步增加。根据联合国 2020 年世界人口老龄化数据库,预计到 2050 年,全球将有 15 亿老年人,高于 2020 年的 7.27 亿。老年人患慢性病的风险更高,这推动了慢性病管理市场的需求。由于老年人易患各种疾病,尤其是慢性病,公司的主要目标是在市场上推出先进和改进的解决方案。
市场製约因素
长期护理中缺乏适当的沟通
实现优质的患者护理取决于有效的沟通,这也是提供者与患者互动的基础。当患者感到被理解和听到时,医疗保健专业人员可以提供更好的护理。此外,在咨询后,相同的患者倾向于遵循推荐的治疗过程。大流行给患者的期望和行为带来了重大变化。
按疾病类型划分的前景
慢性病管理市场按疾病类型分为心血管疾病、糖尿病、癌症、哮喘、慢性阻塞性肺病等。 2021 年,肿瘤学部门在慢性病管理市场的收入份额可观。这是由于个体中各种癌症的病例数量不断增加。癌症类型通常以其首次出现的器官或组织命名。
按类型划分的前景
慢性病管理市场按类型细分为解决方案和服务。解决方案部门将在 2021 年占据慢性病管理市场的最高收入份额。慢性病管理系统和市场的增长是由对在医疗保健中使用云和本地解决方案的认识不断提高推动的。
最终用户的观点
按最终用户,慢性病管理市场分为医疗保健提供者、医疗保健支付者等。 2021 年,医疗保健支付者部分在慢性病管理市场中占据了可观的收入份额。由于人口老龄化的增加和慢性病的发生,市场正在扩大。确定服务价格、处理索赔、收取付款和支付提供者的组织包括医疗保健支付者,例如 Medicare、健康计划提供者和 Medicaid。
区域展望
按地区分析了北美、欧洲、亚太地区和拉美地区的慢性病管理市场。北美已成为慢性病管理市场的关键区域,2021 年收入份额最高。这可以通过该地区慢性病发病率的增加、关键人物的存在和医疗保健的改善来解释。例如,每 10 名美国人中就有 6 人患有至少一种慢性病,例如糖尿病、癌症、心脏病或中风,这些都是导致该国医疗保健费用上涨的主要原因,导致死亡和是主要原因的残疾。
市场参与者采取的主要策略是产品发布。根据基数矩阵中的分析,ExlService Holdings, Inc. 是慢性病管理市场的领先先驱。 Health Catalyst, Inc.、AllScripts Healthcare Solutions, Inc. 和 Koninklijke Philips N.V. 等公司是慢性病管理市场的领先创新者。
The Global Chronic Disease Management Market size is expected to reach $9.9 billion by 2028, rising at a market growth of 11.7% CAGR during the forecast period.
The treatment of chronic diseases is managed by an integrated care strategy that involves patient education, screenings, checkups, monitoring, and coordination of care. While lowering healthcare expenses, it can raise life quality. An ailment that lasts for a year or longer, necessitates continuing medical care, and/or restricts a person's everyday activities is often referred to as a chronic disease.
Heart disease, chronic respiratory diseases, high blood pressure, diabetes, stroke, asthma, and cancer are a few of the most prevalent chronic illnesses. Metabolic and behavioural risk factors are the two primary risks linked to chronic disease. In contrast to the metabolic risk factors, which include obesity, hyperglycemia, and high blood pressure, the behavioural risk factor includes the use of tobacco, inactivity, unhealthy eating, and problematic alcohol use.
The increase in the elderly population and the rise in the prevalence of numerous chronic diseases, such as cancer and others, are the main drivers of the chronic disease management market's expansion. For example, as per the NCBI, 43 percent of all diseases and 60 percent of deaths worldwide are caused by chronic conditions. Additionally, non-communicable diseases impact people of all ages, geographical areas, and nations, according to the WHO (NCDs).
Additionally, the growth of the Chronic Disease Management Market is driven by the rise in acceptance of chronic disease management as a result of the incorporation of IT solutions. To help people effectively manage their disease, a variety of initiatives have been developed by healthcare professionals, organizations, and payers. Such initiatives, in contrast to conventional patient education, place a stronger emphasis on problem-solving as well as social coping strategies in order to increase self-efficacy in the field of care management.
COVID-19 Impact Analysis
The market for managing chronic diseases continues to benefit from COVID-19's overall effects. The rising incidence of COVID-19 has increased the requirement for precise diagnostic and therapeutic tools in a number of nations. The ability of healthcare providers to easily connect solutions like patient management, EHR, and care management with healthcare payer solutions like claim management & payment management has shown to be quite beneficial in this regard. Additionally, the disease's quick global spread has led to lockdowns and other limitations, which has raised the demand for electronic data transfer & claim administration. In the upcoming years, it is anticipated that this will enhance the popularity of chronic disease management.
Market Growth Factors
Rising Cases Of Various Chronic Diseases
During the forecast period, the incidence of chronic diseases like diabetes, cancer, high blood pressure, and others would increase, boosting the market's growth rate. Given that older people are more likely to be obese and have diabetes, chronic diseases are a significant source of worry for them. Numerous patients undergoing chronic disease management face socioeconomic obstacles that make it challenging for them to routinely obtain and pay for healthcare treatments. If these patients lack the necessary funds, they may postpone or forego necessary therapy.
Growing Number Of Geriatric Population
Because life expectancy has increased over time, there are steadily more people in their 60s and older. As per the United Nations Database on World Population Ageing 2020, that there will be 1.5 billion elderly people worldwide by 2050, up from 727 million in 2020. The danger of developing chronic diseases is higher in the elderly, which drives up demand for the chronic disease management market. Since older population are more prone to various disease, particularly chronic ones, companies are majorly aiming at the introduction of advanced and improved solutions in the market.
Market Restraining Factors
Lack Of Proper Communication In Chronic Care Management
Delivering high-quality patient care depends on effective communication, which is also the cornerstone of provider-patient interactions. Providers are better able to offer the proper treatment when patients feel understood and heard. Long after the appointment has ended, the same patients are more willing to follow the recommended treatment strategies. The pandemic caused a profound change in patient expectations and behaviour.
Disease Type Outlook
Based on disease type, the chronic disease management market is segmented into Cardiovascular diseases, Diabetes, Cancer, Asthma, Chronic obstructive pulmonary disorders, and Others. The cancer segment witnessed a promising revenue share in the chronic disease management market in 2021. It is owing to the growing cases of various types of cancers among individuals. Typically, cancer types are called for the organs or tissues in which they first appear.
Type Outlook
On the basis of type, the chronic disease management market is bifurcated into Solutions and Services. The solutions segment acquired the highest revenue share in the chronic disease management market in 2021. The expansion of the chronic illness management system and the market are driven by the increased awareness of the utilization of cloud-based and on-premise solutions in healthcare.
End-User Outlook
By end-user, the chronic disease management market is classified into Healthcare Providers, Healthcare Payers and Others. Healthcare Payers segment procured a significant revenue share in the chronic disease management market in 2021. The market is expanding as a result of the increase in geriatric population and the incidence of chronic diseases. Organizations that determine service prices, process claims, collect payments, and pay provider claims include payers in the health care sector like Medicare, health plan providers, and Medicaid.
Regional Outlook
Region-wise, the chronic disease management market is analyzed across North America, Europe, Asia Pacific and LAMEA. North America emerged the leading region in the chronic disease management market with the highest revenue share in 2021. This is explained by an increase in chronic disease occurrences, the presence of important figures, and improvements in healthcare in the area. For instance, six out of ten Americans have at least one chronic illness, such as diabetes, cancer, heart disease, or a stroke, all of which are major contributors to this country's rising healthcare expenses and are major causes of mortality and disability.
The major strategies followed by the market participants are Product Launches. Based on the Analysis presented in the Cardinal matrix; ExlService Holdings, Inc. is the major forerunner in the Chronic Disease Management Market. Companies such as Health Catalyst, Inc., AllScripts Healthcare Solutions, Inc. and Koninklijke Philips N.V. are some of the key innovators in Chronic Disease Management Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Infosys Limited, ExlService Holdings, Inc., Health Catalyst, Inc., AllScripts Healthcare Solutions, Inc., Koninklijke Philips N.V., Cognizant Technology Solutions Corporation, Casenet, LLC, Cedar Gate Technologies, Clinical Excellence, Inc., and Altruista Health, Inc.
Recent strategies deployed in Chronic Disease Management Market
Product Launches and Product Expansions:
May-2022: Koninklijke Philips introduced various new innovative additions to its prevailing healthcare solutions portfolio. These additions involve ultra-low contrast percutaneous coronary intervention (ULC-PCI), EchoNavigator 2.0, Dynamic Coronary Roadmap Software, iFR Co-registration, and IVUS Co-registration. ULC-PCI would assist interventionists to perform percutaneous coronary intervention with more confidence and clarity and at a much more decreased cost, EchoNavigator 4.0 would help in complicated heart disease treatment like heart valve repair or therapy.
Oct-2021: EXL launched a new omnichannel Patient Engagement Platform. This platform utilizes real-world patient information and powerful analytics to boost highly customized care management programs for health plans and self-insured employers.
Aug-2021: Casenet unveiled the TruCare care management solution integrated with clinical solutions for telehealth and remote patient monitoring (RPM) on the ZyterHealth platform. This integration of clinical data and care management data on the ZyterHealth platform would complement the objectives of value-based care programs by delivering providers and payers a more holistic view of both the medical issues and social problems affecting the patient's healthcare experience.
Nov-2020: Royal Philips launched a non-invasive Philips Ventilator BiPAP A40 EFL. The new device would assist pulmonologists to identify COPD patients with expiratory flow limitation (EFL) and treat them with targeted therapy to reduce symptoms and provide better comfort during sleep.
Sep-2020: Casenet introduced Zyter Home Health and Remote Patient Monitoring (RPM). This product is a complete, ready-to-implement solution that would expand healthcare and monitoring beyond the conventional environment, which would make it simpler for patients to participate in their own care and actively handle their conditions.
Jun-2020: Health Catalyst released comprehensive quality measures solution that would integrate its Data Operating System with the application of a scalable measure. This solution is developed to enhance provider quality measurement. To offer customers one comprehensive quality performance system by integrating comprehensive data from DOS with complete measures, visualizations, and workflows into one product.
Acquisitions and Mergers:
Dec-2021: Royal Philips acquired Vesper Medical, a medical technology company. This acquisition aimed to enable Philips to expand its diagnostic as well as therapeutic device portfolio with an improved venous stent portfolio to cure deep venous disease.
Nov-2021: Royal Philips took over Cardiologs, a France-based medical technology company. This acquisition aimed to complement Philips' prevailing portfolio of cardiac care solutions. This involves real-time patient monitoring, telehealth, therapeutic devices, and informatics for the hospital.
Oct-2021: Altruista Health acquired Wellframe, a digital health management company. This acquisition aimed to boost HealthEdge's portfolio of SaaS solutions over payer workflow operations and would mark HealthEdge's entry into member engagement.
Jan-2021: Cedar Gate Technologies took over Enli Health Intelligence, a provider of population health management technology solutions. This acquisition aimed to expand Cedar Gate's enterprise value-based care platform with the cohort, population, and patient management technologies, incorporating risk & quality measures, gaps in care identification, and patient outreach opportunities, for better results and sustainable financial outcomes.
Dec-2020: Philips took over BioTelemetry, a leading provider of remote cardiac diagnostics and monitoring. This acquisition aimed to strengthen Philips's offering of remote care products. Along with that, the acquisition would complement Philips' cardiac care portfolio, and its strategy to transform the delivery of care along the health continuum with combined solutions.
Partnerships, Collaborations and Agreements:
Aug-2022: Health Catalyst joined hands with LifePoint Health, an American company that provides healthcare services. This collaboration aimed to improve patient care and enhance results across the health system's network. In this collaboration, LifePoint Health would deploy Health Catalyst's suite of patient care solutions, involving a range of data collection and analytics platforms.
Mar-2022: Cognizant, the parent company of TriZetto Software Group collaborated with Microsoft, an American multinational technology corporation. This collaboration aimed to improve remote patient monitoring for improved medical care. Using data analytics, safe cloud technology, and interoperability products, this collaboration would deliver a unique, scalable solution that would focus to connect providers & patients and improve the timeliness, quality, and personalization of healthcare.
Approvals and Trials:
Mar-2022: Royal Philips got approval for the Philips Capsule Surveillance solution from the U.S. Food & Drug Administration (FDA). This FDA clearance of the new release of clinical surveillance solution would allow more integrated viewing options under EMR and HIT tools via the safe web-based customer interface.
Nov-2021: Royal Philips got 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Liver Fat Quantification tools. This release of ultrasound systems EPIQ Elite and Affiniti would bring the cost and accessibility benefits of sonography to the diagnosis of early-stage liver disease.
Market Segments covered in the Report:
By Type
By End User
By Disease Type
By Geography
Companies Profiled
Unique Offerings from KBV Research
Asia Pacific Asthma Market by Country, 2022 - 2028, USD Million 140
List of Figures